فهرست:
فصل اول: معرفی پژوهش
بیان مسئله
اهداف پژوهش
فصل دوم: دانستنی های موجود در پژوهش
- چارچوب پنداشتی
سبب شناسی
تظاهرات بالینی
یافته های آزمایشگاهی
تشخیص افتراقی
درمان
- مروری بر مطالعات انجام شده
فصل سوم: متدولوژی تحقیق
فصل چهارم: یافته های پژوهش
فصل پنجم: بحث
فصل ششم: نتیجه گیری و پیشنهادات
فهرست منابع
نمودارهای مربوط به جداول داده ها
پرسشنامه
منبع:
D'Orazio JA, Neely J, Farhoudi N. ITP in Children: Pathophysiology and Current Treatment Approaches. J Pediatr Hematol Oncol. 2013 Jan;35(1):1-13.
Anoop P. Immune thrombocytopenic purpura: historical perspective, current status, recent advances and future directions. Indian Pediatr. 2012 Oct;49(10):811-8.
Terrel DR,Beebe LA, Vesely SK,Neas BR, Segal JB, George JN. Theincidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J hematol. 2010:85:174-80.
Nelson Textbook of Pediatrics, 476 Platelet and Blood Vessel Disorders, 476.1 Treatment of Idiopathic Thrombocytopenic Purpura. 19th edition.
علوی ثمین، ملک فاطمه، اقبالی عزیز، ارزانیان محمدتقی، شمسیان بی بی شهین، آذرگشب اذن اله. ایمیون ترومبوسیتوپنیک پورپورا و عوامل همراه در بیماران مراجعه کننده به بیمارستان کودکان مفید طی سال های 1387-1382 خون پاییز 1388; 6(3 (پیاپی 24)):165-173.
بنی هاشم عبداله، هیرادفر سیمین، کیانی محمدعلی. مقایسه اثر درمانی و عوارض جانبی پردنیزولون، ایمونوگلوبولین وریدی و آنتی Rh آنتی بادی در بیماران مبتلا به پورپورای ترومبوسیتوپنیک ایدیوپاتیک. مجله علمی پزشکی پاییز 1386; 6(3 (مسلسل 54)):285-289.
Celik M, Bulbul A, Aydogan G, Tugcu D, Uslu S, Dursun M. Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura. J Thromb Thrombolysis. 2012 Sep 6. [Epub ahead of print]
George JN, El-Harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. 5th ed. New York, NY: McGraw-Hill; 1995:1315-1329.
Moake JL. Thrombotic thrombocytopenic due to enhanced hemolytic uremic syndrome. Syndrom. Holfman R. Benz Jr El, Sanforrd JS.Bruice F. Harvey JC.In Hematology basic principle and practice, Churchill Livingstone New York. P 1495-1513.1991
Guthrie Jr TH, Brannan DP, Prisant LM. Idiopathic thrombocytopenic purpura in the older adult patient. The American journal of the medical sciences. 1988; 296(1):17.
Werlhof PG. Opera Omnia. Hanover: Helwing, 1775:748. In: Major RH, editor. Classic Descriptions of Disease. 3rd ed. Springfield, IL: CC Thomas, 1965
Glanz J, France E, Xu S, Hayes T, Hambidge S. population-based, multisite cohort study of thepredictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 2008; 121(3): e506-12
Zeller B, Rujon fie J. Childhood ITP in the N ordic countries epidemiology and predictors of chronic disease. Acta paediatrica 2005; 94(2): 178-84.
Pratt EL, Tarantino MD, Wagner D, Hirsch Pescovitz O, Bowyer S, Shapiro AD. Prevalence of elevated Antithyroid antibodies and Antinuclear antibodies in children with ITP. Am J Hematol 2005; 79(3): 175-9.
Kalpatthi R, Bussel JB. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr 2008; 20(1): 8-16.
Kuhne T, Imbach P. Management of children withacute and chronic immune thrombocytopentic Purpura. Transfusion Science 1998; 19(3) : 26)-268.
Nathan & Oski. Hematology of infancy & childhood, Saunders Elsevier, 1559, 7th edition.
Imbach P, d’Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, et al. High-dose intravenous gamma globulin for idiopathic thromboctyopenic purpura in childhood. Lancet. 1981;1:1228-31.
Wintrobe MM, Cartwright GE, Palmer JG, Kuhns WJ, Samuels LT. Effect of corticotrophin and cortisone on the blood in various disorders in man. Arch Int Med. 1951;88:310-36.
George JN, Woolf SH, Raskob GE, Wasser J, Aledort L, Ballem P, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88(1):3-40.
Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-95
Holt D, Brown J, Terrill K, et al. Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura. Pediatrics. 2003;111(1):87-90.
Hedlund-Treutiger I, Henter JI, Elinder G. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003 Feb;25(2):139-44.
Hollander LL, Leys CM, Weil BR, Rescorla FJ. Predictive value of response to steroid therapy on response to splenectomy in children with immune thrombocytopenic purpura. Surgery. 2011 Oct;150(4):643-8.
Benesch M, Kerbl R, Lackner H, et al. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. J Pediatr Hematol Oncol. 2003 Oct;25(10):797-800.